untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:18:05Z</responseDate>
<request identifier=oai:HAL:hal-01467550v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01467550v1</identifier>
<datestamp>2017-12-22</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
<setSpec>collection:INRA</setSpec>
<setSpec>collection:HCL</setSpec>
<setSpec>collection:SANTE_PUB_INSERM</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:APHP</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UNIV-AMU</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:AGREENIUM</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25)</title>
<creator>Meunier, Sandrine</creator>
<creator>d'oiron, Roselyne</creator>
<creator>Chambost, H.</creator>
<creator>Dolimier, E.</creator>
<creator>Guillet, Benoît</creator>
<contributor>Hôpital Louis-Pradel [Lyon] ; Université Claude Bernard Lyon 1 (UCBL) - Hospices Civils de Lyon - Hôpital Louis-Pradel</contributor>
<contributor>AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)</contributor>
<contributor>Nutrition, obésité et risque thrombotique (NORT) ; Institut National de la Recherche Agronomique (INRA) - Aix Marseille Université (AMU) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Laboratoire d'hématologie biologique [Hôpital de la Timone - Hôpital Nord - APHM] ; Aix Marseille Université (AMU) - Assistance Publique - Hôpitaux de Marseille (APHM) - Hôpital de la Timone [CHU - APHM] (TIMONE)</contributor>
<contributor>Shire France</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Baxalta</contributor>
<description>International audience</description>
<source>ISSN: 0049-3848</source>
<source>Thrombosis Research</source>
<publisher>Elsevier</publisher>
<identifier>hal-01467550</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01467550</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01467550/document</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01467550/file/Choice%20of%20factor%20VIII-IX%20regime.pdf</identifier>
<source>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01467550</source>
<source>Thrombosis Research, Elsevier, 2017, 151, pp.17-22. 〈10.1016/j.thromres.2016.12.023〉</source>
<identifier>DOI : 10.1016/j.thromres.2016.12.023</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.thromres.2016.12.023</relation>
<identifier>PUBMED : 28088606</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/28088606</relation>
<language>en</language>
<subject lang=en>Factor VIII</subject>
<subject lang=en>Factor IX</subject>
<subject lang=en>Prophylaxis</subject>
<subject lang=en>On-demand treatment</subject>
<subject lang=en>Age groups</subject>
<subject lang=en>Haemorrhage</subject>
<subject>[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie</subject>
<subject>[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>Introduction: The value and challenges of long-term prophylaxis (LTP) in adolescents and young adults need further characterisation.Aim: To determine the proportions of adolescents and young adults with severe or moderately severe haemophilia in France under LTP and treatment on demand (OD).Methods: Patients 15 to 25 years old with haemophilia A or B, factor VIII/IX ≤ 2% and no current inhibitor could be included if they had been under factor VIII/IX treatment at least 12 months and kept a treatment and bleeding diary.Results: LTP was administered to 169/212 patients (79.7%) and OD treatment to 40/212 patients (18.9%). The most frequent reasons for initiating LTP were joint bleeding, target joints and frequent bleeds; whereas OD treatment was most often selected on the basis of mild bleeding phenotype or because of constraints on LTP. The mean annual bleed rate (ABR) in the OD group (6.33) was higher than in the LTP group (3.07, p < 0.001). Mean ABR did not differ significantly between age strata (15–18, > 18–21 and > 21–25 years), but was significantly higher for patients with severe haemophilia (4.02) as compared to those with moderate haemophilia (1.97, p = 0.002). No significant difference was observed in mean ABR for joint bleeds between the LTP and OD groups. Physician reported LTP compliance was good or excellent in 97.0% of patients.Conclusion: LTP is the predominant factor VIII/IX treatment among adolescents and young adults with severe or moderately severe haemophilia in France. LTP was associated with low ABR and high compliance. © 2017 The Authors</description>
<date>2017</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
